Teresa Otto’s Post

A key decision when considering #analyticaltestingmethods for #biotherapeutics is whether to pursue an in-house #assaydevelopment strategy or to adopt a commercial kit. This #infographic distills four illustrative case studies to explain the real-life pitfalls that may be encountered when pursuing an in-house #assay development strategy for #advancedtherapy product characterization. https://buff.ly/4e5ROIp Recently published content that covers the steps and challenges that go into in-house development of a #residualDNAassay in detail, and explores innovative research in this space, includes an #article and an on-demand #webinar Article: https://buff.ly/4deeh4F Webinar : https://buff.ly/4deehlb These are just a few of the resources available on our Characterization & Analytics Hub. The hub explores a new generation of analytical tools designed to meet the specific needs of #viralvector and cell-based therapy production, offering the enhanced speed, sensitivity, and robustness that the industry requires. Once you’ve read your first piece of content, all the rest is available to you open access Access the hub below: https://buff.ly/496Nshd

A key decision when considering #analyticaltestingmethods for #biotherapeutics is whether to pursue an in-house #assaydevelopment strategy or to adopt a commercial kit. This #infographic distills four illustrative case studies to explain the real-life pitfalls that may be encountered when pursuing an in-house #assay development strategy for #advancedtherapy product characterization. https://buff.ly/4e5ROIp Recently published content that covers the steps and challenges that go into in-house development of a #residualDNAassay in detail, and explores innovative research in this space, includes an #article and an on-demand #webinar Article: https://buff.ly/4deeh4F Webinar : https://buff.ly/4deehlb These are just a few of the resources available on our Characterization & Analytics Hub. The hub explores a new generation of analytical tools designed to meet the specific needs of #viralvector and cell-based therapy production, offering the enhanced speed, sensitivity, and robustness that the industry requires. Once you’ve read your first piece of content, all the rest is available to you open access Access the hub below: https://buff.ly/496Nshd

🇨🇭 It's not all about CDRs. Discover how #ML-guided protein design is breaking boundaries by optimizing binding affinity, expression, and stability in surprising ways. 👇 Daniel Danciu will share insights on how even significant #CDR modifications—including CDR3—can retain strong binding properties when driven by a custom-conditioned #protein language model. Plus, learn how active-learning can supercharge antibody optimization from early-stage leads. 𝐖𝐡𝐞𝐧? October 9th at 12:45 👑 Franziska Geiger, Jonathan D. Ziegler & myself are looking forward to seeing you there & answer any questions 😎 Cradle x BioTechX

A key decision when considering #analyticaltestingmethods for #biotherapeutics is whether to pursue an in-house #assaydevelopment strategy or to adopt a commercial kit. This #infographic distills four illustrative case studies to explain the real-life pitfalls that may be encountered when pursuing an in-house #assay development strategy for #advancedtherapy product characterization. https://buff.ly/4e5ROIp Recently published content that covers the steps and challenges that go into in-house development of a #residualDNAassay in detail, and explores innovative research in this space, includes an #article and an on-demand #webinar Article: https://buff.ly/4deeh4F Webinar : https://buff.ly/4deehlb These are just a few of the resources available on our Characterization & Analytics Hub. The hub explores a new generation of analytical tools designed to meet the specific needs of #viralvector and cell-based therapy production, offering the enhanced speed, sensitivity, and robustness that the industry requires. Once you’ve read your first piece of content, all the rest is available to you open access Access the hub below: https://buff.ly/496Nshd

🚨 Live Event Tomorrow 12 November 2024, Tuesday. Sign up now! Join Dr. Ovidiu Novac to learn about how Organ-on-a-chip (OOC) technology can be leveraged to generate human-relevant DILI insights to identify mechanisms of toxicity that better guide in vivo studies and highlight potential risks long before first-in-human trails. 💡Recreate organ functionality with our Liver-on-a-chip model 💡Predict human risk using the PhysioMimix DILI assay to predict human risk 💡Identify different mechanisms of hepatotoxiciy 💡Evaluate how OOC technology modernizes you drug development process 👉Register here to secure your spot https://lnkd.in/eqCchS-f #CNBioAt #OrganOnAChip #DILI #Hepatotoxicity #DrugSafety

It's day 3 of #ASCO24! Stop by booth #22157 and meet members of the BostonGene team to learn more about our #AI-powered multiomics platform that expedites #research and drug development while precisely matching each #patient with the best available therapy!

"But I've never heard of your company." 🤔 I get it. The cell therapy world moves fast, and you're under pressure to get everything right the first time for your patients. Why wouldn't you just go with one of the legacy GMP protein suppliers? Here's just a few reasons Proteintech Group might be a better fit for your project: 🔵 Native human proteins produced in HEK293 🔵 Animal component-free and Xeno-free production process 🔵 In-house regulatory support 🔵 ISO13485 certified facility in Rosemont, IL 🔵 On-site audits welcome 🔵 Identical expression, production, and operating processes for RUO and GMP products (so you can switch seamlessly as you transition from R&D to manufacturing) And in my humble opinion, the most important asset is our phenomenal team.💪Because we're a smaller company, we have the flexibility to be your partner instead of just another supplier. We can coordinate schedules and lots, provide documentation support, and quickly adjust as your needs change. Ready to get your manufacturing show on the road? Send me a message! #celltherapy #GMPmanufacturing #cytokines #growthfactors

𝗗𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀? 𝗪𝗲'𝘃𝗲 𝗴𝗼𝘁 𝘆𝗼𝘂𝗿 𝗯𝗮𝗰𝗸! If you are attending #SwissBiotechDay in Basel, we're available at booth #75, ready to hear about your projects and your needs. Our team is here to help you overcome roadblocks and optimize your path to successful drug development with protein crystallography. Stop by and let's chat! #SwissBiotechDay #Innovation #DrugDiscovery #StructuralBiology

Two months after ELRIG UK Drug Discovery, it’s great to see the conversations and insights continuing! At the event, we shared updates on our SITESEEKER screening platform, identifying novel druggable sites across the human proteome to advance future therapies. If you didn’t get the chance to stop by, check out our poster, “Uncovering New Pathways for Targeted Protein Degradation", highlighting SITESEEKER’s ability to target E3 ligases with small molecules for effective protein degradation. Read our poster on News Medical: https://lnkd.in/eAEnS_f6 #TPD #DegraderTherapeutics #ProteinDegradation

Join our webinar on December 4'th and get free month of our AI tool for generative drug discovery